In particular, given that pharmaceutical inhibition of PDGFRβ efficiently promotes cell death of BRCA1-deficient tumor cells, it indicates the potential to tailor specific therapies to BLBC patients with BRCA1 deficiency. The gene discussed is BRCA1; the disease is neoplasm.